$JAZZ
Jazz Pharmaceuticals PLC Stock $jazz

$jazz Overview Financials Valuation SEC Filings Company Website

2020 Q1 Form 10-Q Financial Statement

#000123252420000034 Filed on May 05, 2020

Income Statement

Concept	2020 Q1	2019 Q1
Revenue	$534.7M	$508.2M
YoY Change	5.22%	14.3%
Cost Of Revenue	$28.70M	$33.50M
YoY Change	-14.33%	-1.18%
Gross Profit	$501.5M	$469.8M
YoY Change	6.75%	15.46%
Gross Profit Margin	93.8%	92.45%
Selling, General & Admin	$208.4M	$167.9M
YoY Change	24.09%	-18.95%
% of Gross Profit	41.55%	35.75%
Research & Development	$86.11M	$60.11M
YoY Change	43.26%	-4.09%
% of Gross Profit	17.17%	12.79%
Depreciation & Amortization	$4.527M	$3.539M
YoY Change	27.92%	-4.92%
% of Gross Profit	0.9%	0.75%
Operating Expenses	$294.5M	$228.1M
YoY Change	29.14%	-36.09%
Operating Profit	-$189.7M	$133.7M
YoY Change	-241.82%	52.31%
Interest Expense	-$18.50M	-$17.92M
YoY Change	3.2%	-13.02%
% of Operating Profit		-13.4%
Other Income/Expense, Net
YoY Change
Pretax Income	-$209.3M	$115.2M
YoY Change	-281.67%	75.96%
Income Tax	-$51.30M	$29.10M
% Of Pretax Income		25.26%
Net Earnings	-$157.8M	$85.20M
YoY Change	-285.25%	85.26%
Net Earnings / Revenue	-29.52%	16.77%
Basic Earnings Per Share	-$2.82	$1.49
Diluted Earnings Per Share	-$2.82	$1.47
COMMON SHARES
Basic Shares Outstanding	55.96M shares	57.21M shares
Diluted Shares Outstanding	55.96M shares	58.08M shares

Balance Sheet

Concept	2020 Q1	2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$981.6M	$832.5M
YoY Change	17.91%	17.55%
Cash & Equivalents	$701.6M	$547.5M
Short-Term Investments	$755.3M	$640.1M
Other Short-Term Assets	$94.30M	$62.99M
YoY Change	49.72%	0.19%
Inventory	$85.61M	$60.71M
Prepaid Expenses	$38.82M	$28.97M
Receivables	$317.3M	$320.5M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$1.518B	$1.306B
YoY Change	16.24%	15.92%
LONG-TERM ASSETS
Property, Plant & Equipment	$129.6M	$105.0M
YoY Change	23.44%	-41.34%
Goodwill	$909.2M	$920.0M
YoY Change	-1.17%	-4.22%
Intangibles	$2.239B	$2.679B
YoY Change	-16.45%	-9.27%
Long-Term Investments
YoY Change
Other Assets	$47.11M	$40.74M
YoY Change	15.64%	77.23%
Total Long-Term Assets	$3.698B	$3.975B
YoY Change	-6.97%	-4.47%
TOTAL ASSETS
Total Short-Term Assets	$1.518B	$1.306B
Total Long-Term Assets	$3.698B	$3.975B
Total Assets	$5.215B	$5.280B
YoY Change	-1.23%	-0.13%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$66.31M	$42.67M
YoY Change	55.4%	-9.09%
Accrued Expenses	$261.0M	$273.1M
YoY Change	-4.4%	13.51%
Deferred Revenue	$4.176M	$4.720M
YoY Change	-11.53%	-37.05%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due	$33.39M	$33.39M
YoY Change	0.0%	-26.0%
Total Short-Term Liabilities	$396.1M	$414.0M
YoY Change	-4.32%	10.22%
LONG-TERM LIABILITIES
Long-Term Debt	$1.577B	$1.565B
YoY Change	0.75%	1.84%
Other Long-Term Liabilities	$117.3M	$105.3M
YoY Change	11.39%	-45.23%
Total Long-Term Liabilities	$1.694B	$1.671B
YoY Change	1.42%	-3.39%
TOTAL LIABILITIES
Total Short-Term Liabilities	$396.1M	$414.0M
Total Long-Term Liabilities	$1.694B	$1.671B
Total Liabilities	$2.090B	$2.085B
YoY Change	0.28%	-0.96%
SHAREHOLDERS EQUITY
Retained Earnings	$770.9M	$845.9M
YoY Change	-8.86%	-7.82%
Common Stock	$2.294B	$2.131B
YoY Change	7.68%	8.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$2.809B	$2.730B
YoY Change
Total Liabilities & Shareholders Equity	$5.215B	$5.280B
YoY Change	-1.23%	-0.13%

Cashflow Statement

Concept	2020 Q1	2019 Q1
OPERATING ACTIVITIES
Net Income	-$157.8M	$85.20M
YoY Change	-285.25%	85.26%
Depreciation, Depletion And Amortization	$4.527M	$3.539M
YoY Change	27.92%	-4.92%
Cash From Operating Activities	$273.0M	$202.3M
YoY Change	34.96%	20.85%
INVESTING ACTIVITIES
Capital Expenditures	$4.830M	$7.948M
YoY Change	-39.23%	-211.94%
Acquisitions
YoY Change
Other Investing Activities	$160.0M	$230.0M
YoY Change	-30.43%	-611.11%
Cash From Investing Activities	-$60.08M	$166.1M
YoY Change	-136.18%	-418.42%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$139.1M	$111.2M
YoY Change	24.99%	222.03%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-$147.7M	-$130.3M
YoY Change	13.3%	173.99%
NET CHANGE
Cash From Operating Activities	$273.0M	$202.3M
Cash From Investing Activities	-$60.08M	$166.1M
Cash From Financing Activities	-$147.7M	-$130.3M
Net Change In Cash	$64.26M	$237.8M
YoY Change	-72.98%	254.28%
FREE CASH FLOW
Cash From Operating Activities	$273.0M	$202.3M
Capital Expenditures	$4.830M	$7.948M
Free Cash Flow	$268.1M	$194.3M
YoY Change	38.0%	11.38%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2020Q1	dei	Amendment Flag AmendmentFlag	false
CY2020Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2020Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001232524
CY2020Q1	dei	Entity Registrant Name EntityRegistrantName	Jazz Pharmaceuticals plc
CY2019Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax	249000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax	579000	USD
CY2020Q1	dei	Document Type DocumentType	10-Q
CY2020Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2020Q1	dei	Document Period End Date DocumentPeriodEndDate	2020-03-31
CY2020Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2020Q1	dei	Entity File Number EntityFileNumber	001-33500
CY2020Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	L2
CY2020Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	98-1032470
CY2020Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	Fifth Floor, Waterloo Exchange,
CY2020Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Waterloo Road
CY2020Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Dublin 4
CY2020Q1	dei	Entity Address Country EntityAddressCountry	IE
CY2020Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	D04 E5W7
CY2020Q1	dei	Country Region CountryRegion	353
CY2020Q1	dei	City Area Code CityAreaCode	1
CY2020Q1	dei	Local Phone Number LocalPhoneNumber	634-7800
CY2020Q1	dei	Security12b Title Security12bTitle	Ordinary shares, nominal value $0.0001 per share
CY2020Q1	dei	Trading Symbol TradingSymbol	JAZZ
CY2020Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2020Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020Q1	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2020Q1	dei	Entity Small Business EntitySmallBusiness	false
CY2020Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	55330359	shares
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	701602000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	637344000	USD
CY2020Q1	us-gaap	Investments Investments	280000000	USD
CY2019Q4	us-gaap	Investments Investments	440000000	USD
CY2020Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	317301000	USD
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	355987000	USD
CY2020Q1	us-gaap	Inventory Net InventoryNet	85610000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	78608000	USD
CY2020Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	38824000	USD
CY2020Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020Q1	dei	Entity Shell Company EntityShellCompany	false
CY2019Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	39434000	USD
CY2020Q1	us-gaap	Other Assets Current OtherAssetsCurrent	94300000	USD
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	78895000	USD
CY2020Q1	us-gaap	Assets Current AssetsCurrent	1517637000	USD
CY2019Q4	us-gaap	Assets Current AssetsCurrent	1630268000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	129562000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	131506000	USD
CY2020Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	135976000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	139385000	USD
CY2020Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2238658000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2440977000	USD
CY2020Q1	us-gaap	Goodwill Goodwill	909226000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	920018000	USD
CY2020Q1	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	230242000	USD
CY2019Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	221403000	USD
CY2020Q1	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	6887000	USD
CY2019Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	7426000	USD
CY2020Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	47107000	USD
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	47914000	USD
CY2020Q1	us-gaap	Assets Assets	5215295000	USD
CY2019Q4	us-gaap	Assets Assets	5538897000	USD
CY2020Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	66308000	USD
CY2019Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	47545000	USD
CY2020Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	261041000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	267873000	USD
CY2020Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	33387000	USD
CY2019Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	33387000	USD
CY2020Q1	us-gaap	Taxes Payable Current TaxesPayableCurrent	31211000	USD
CY2019Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	10965000	USD
CY2020Q1	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	4176000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	4720000	USD
CY2020Q1	us-gaap	Liabilities Current LiabilitiesCurrent	396123000	USD
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	364490000	USD
CY2020Q1	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	4225000	USD
CY2019Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	4861000	USD
CY2020Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1576984000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1573870000	USD
CY2020Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	147110000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	151226000	USD
CY2020Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	165095000	USD
CY2019Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	224095000	USD
CY2020Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	117258000	USD
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	109374000	USD
CY2020Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q1	us-gaap	Common Stock Value CommonStockValue	6000	USD
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	6000	USD
CY2020Q1	jazz	Nonvoting Euro Deferred Shares NonvotingEuroDeferredShares	55000	USD
CY2019Q4	jazz	Nonvoting Euro Deferred Shares NonvotingEuroDeferredShares	55000	USD
CY2020Q1	jazz	Capital Redemption Reserve CapitalRedemptionReserve	472000	USD
CY2019Q4	jazz	Capital Redemption Reserve CapitalRedemptionReserve	472000	USD
CY2020Q1	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2294474000	USD
CY2019Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	2266026000	USD
CY2020Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-257436000	USD
CY2019Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-223393000	USD
CY2020Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	770929000	USD
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1067815000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	2808500000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	3110981000	USD
CY2020Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5215295000	USD
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5538897000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	534726000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	508186000	USD
CY2020Q1	jazz	Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment	28657000	USD
CY2019Q1	jazz	Cost Of Product Sales Excluding Amortization Of Acquired Developed Technology And Intangible Asset Impairment CostOfProductSalesExcludingAmortizationOfAcquiredDevelopedTechnologyAndIntangibleAssetImpairment	33506000	USD
CY2020Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	208400000	USD
CY2019Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	167947000	USD
CY2020Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	86107000	USD
CY2019Q1	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	60105000	USD
CY2020Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	62847000	USD
CY2019Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	56885000	USD
CY2020Q1	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	202250000	USD
CY2019Q1	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	56000000	USD
CY2020Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	136139000	USD
CY2019Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2020Q1	us-gaap	Costs And Expenses CostsAndExpenses	724400000	USD
CY2019Q1	us-gaap	Costs And Expenses CostsAndExpenses	374443000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-189674000	USD
CY2019Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	133743000	USD
CY2020Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-18496000	USD
CY2019Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-17922000	USD
CY2020Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1132000	USD
CY2019Q1	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-611000	USD
CY2020Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-209302000	USD
CY2019Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	115210000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-51287000	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	29116000	USD
CY2020Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	182000	USD
CY2019Q1	us-gaap	Income Loss From Equity Method Investments IncomeLossFromEquityMethodInvestments	-893000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-157833000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	85201000	USD
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.82
CY2019Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.49
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.82
CY2019Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.47
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55956000	shares
CY2019Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	57206000	shares
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	55956000	shares
CY2019Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58081000	shares
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-157833000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	85201000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-29990000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-21142000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-4053000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Cash Flow Hedge Gain Loss After Reclassification And Tax OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax	-1741000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-34043000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-22883000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-191876000	USD
CY2019Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	62318000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	3110981000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	13264000	USD
CY2020Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	13547000	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	28731000	USD
CY2020Q1	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	139053000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-34043000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-157833000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	2808500000	USD
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	2757422000	USD
CY2019Q1	us-gaap	Cumulative Effect Of New Accounting Principle In Period Of Adoption CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption	4848000	USD
CY2019Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3057000	USD
CY2019Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	13810000	USD
CY2019Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	27861000	USD
CY2019Q1	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	111249000	USD
CY2019Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-22883000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	85201000	USD
CY2019Q1	us-gaap	Stockholders Equity StockholdersEquity	2730447000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-157833000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	85201000	USD
CY2020Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	62847000	USD
CY2019Q1	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	56885000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	28654000	USD
CY2019Q1	us-gaap	Share Based Compensation ShareBasedCompensation	27552000	USD
CY2020Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	136139000	USD
CY2019Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0	USD
CY2020Q1	us-gaap	Depreciation Depreciation	4527000	USD
CY2019Q1	us-gaap	Depreciation Depreciation	3539000	USD
CY2020Q1	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	202250000	USD
CY2019Q1	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	56000000	USD
CY2020Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-73000	USD
CY2019Q1	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-3000	USD
CY2020Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-63976000	USD
CY2019Q1	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-17053000	USD
CY2020Q1	jazz	Provision For Losses On Accounts Receivable And Inventory ProvisionForLossesOnAccountsReceivableAndInventory	2620000	USD
CY2019Q1	jazz	Provision For Losses On Accounts Receivable And Inventory ProvisionForLossesOnAccountsReceivableAndInventory	528000	USD
CY2020Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	12000000	USD
CY2019Q1	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	11133000	USD
CY2020Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1902000	USD
CY2019Q1	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	738000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-37861000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	56960000	USD
CY2020Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	10235000	USD
CY2019Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	8688000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	17843000	USD
CY2019Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	988000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-323000	USD
CY2019Q1	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-426000	USD
CY2020Q1	jazz	Increase Decrease In Operating Lease Assets IncreaseDecreaseInOperatingLeaseAssets	-3195000	USD
CY2019Q1	jazz	Increase Decrease In Operating Lease Assets IncreaseDecreaseInOperatingLeaseAssets	-2108000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	19604000	USD
CY2019Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1554000	USD
CY2020Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-12198000	USD
CY2019Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-3730000	USD
CY2020Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	20829000	USD
CY2019Q1	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	39726000	USD
CY2020Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1180000	USD
CY2019Q1	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-1874000	USD
CY2020Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	7316000	USD
CY2019Q1	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	6773000	USD
CY2020Q1	jazz	Increase Decrease In Operating Lease Liabilities Noncurrent IncreaseDecreaseInOperatingLeaseLiabilitiesNoncurrent	-3906000	USD
CY2019Q1	jazz	Increase Decrease In Operating Lease Liabilities Noncurrent IncreaseDecreaseInOperatingLeaseLiabilitiesNoncurrent	856000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	272969000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	202253000	USD
CY2020Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	345000000	USD
CY2019Q1	us-gaap	Proceeds From Sale Maturity And Collections Of Investments ProceedsFromSaleMaturityAndCollectionsOfInvestments	345000000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4830000	USD
CY2019Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7948000	USD
CY2020Q1	jazz	Paymentsto Acquire In Process Researchand Development Other Than Through Business Combination PaymentstoAcquireInProcessResearchandDevelopmentOtherThanThroughBusinessCombination	202250000	USD
CY2019Q1	jazz	Paymentsto Acquire In Process Researchand Development Other Than Through Business Combination PaymentstoAcquireInProcessResearchandDevelopmentOtherThanThroughBusinessCombination	56000000	USD
CY2020Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	13000000	USD
CY2019Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0	USD
CY2020Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	185000000	USD
CY2019Q1	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	115000000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-60080000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	166052000	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	13264000	USD
CY2019Q1	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	3057000	USD
CY2020Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	13547000	USD
CY2019Q1	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	13810000	USD
CY2020Q1	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	8347000	USD
CY2019Q1	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	8347000	USD
CY2020Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	139053000	USD
CY2019Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	111249000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-147683000	USD
CY2019Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-130349000	USD
CY2020Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-948000	USD
CY2019Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-112000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	64258000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	237844000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	637344000	USD
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	309622000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	701602000	USD
CY2019Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	547466000	USD
CY2020Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2020Q1	us-gaap	Use Of Estimates UseOfEstimates	<div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and related disclosures in the condensed consolidated financial statements and accompanying notes. Management bases its estimates on historical experience and on assumptions believed to be reasonable under the circumstances. Actual results could differ materially from those estimates.</span></div>
CY2020Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="line-height:120%;padding-top:18px;text-indent:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Risk</span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject us to concentrations of credit risk consist of cash, cash equivalents, investments and derivative contracts. Our investment policy permits investments in U.S. federal government and federal agency securities, corporate bonds or commercial paper issued by U.S. corporations, money market instruments, certain qualifying money market mutual funds, certain repurchase agreements, and tax-exempt obligations of U.S. states, agencies and municipalities and places restrictions on credit ratings, maturities, and concentration by type and issuer. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and investments to the extent recorded on the balance sheet.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We manage our foreign currency transaction risk and interest rate risk within specified guidelines through the use of derivatives. All of our derivative instruments are utilized for risk management purposes, and we do not use derivatives for speculative trading purposes. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, we had foreign exchange forward contracts with notional amounts totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$225.4 million</span></span><span style="font-family:inherit;font-size:10pt;">. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, the outstanding foreign exchange forward contracts had a net liability fair value of </span><span style="font-family:inherit;font-size:10pt;"><span>$3.6 million</span></span><span style="font-family:inherit;font-size:10pt;">. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, we had interest rate swap contracts with notional amounts totaling </span><span style="font-family:inherit;font-size:10pt;"><span>$300.0 million</span></span><span style="font-family:inherit;font-size:10pt;">. These outstanding interest rate swap contracts had a net liability fair value of </span><span style="font-family:inherit;font-size:10pt;"><span>$6.2 million</span></span><span style="font-family:inherit;font-size:10pt;"> as of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">. The counterparties to these contracts are large multinational commercial banks, and we believe the risk of nonperformance is not significant.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We are also subject to credit risk from our accounts receivable related to our product sales. We monitor our exposure within accounts receivable and record a reserve against uncollectible accounts receivable as necessary. We extend credit to pharmaceutical wholesale distributors and specialty pharmaceutical distribution companies, primarily in the U.S., and to other international distributors and hospitals. Customer creditworthiness is monitored and collateral is not required. We monitor deteriorating economic conditions in certain European countries which may result in variability of the timing of cash receipts and an increase in the average length of time that it takes to collect accounts receivable outstanding. Historically, we have not experienced significant credit losses on our accounts receivable and as of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;"> and </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, allowances on receivables were not material. As of </span><span style="font-family:inherit;font-size:10pt;">March 31, 2020</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">two</span><span style="font-family:inherit;font-size:10pt;"> customers accounted for </span><span style="font-family:inherit;font-size:10pt;"><span>88%</span></span><span style="font-family:inherit;font-size:10pt;"> of gross accounts receivable, Express Scripts Specialty Distribution Services, Inc. and its affiliates, or ESSDS, which accounted for </span><span style="font-family:inherit;font-size:10pt;"><span>81%</span></span><span style="font-family:inherit;font-size:10pt;"> of gross accounts receivable, and McKesson Corporation and affiliates, or McKesson, which accounted for </span><span style="font-family:inherit;font-size:10pt;"><span>7%</span></span><span style="font-family:inherit;font-size:10pt;"> of gross accounts receivable. As of </span><span style="font-family:inherit;font-size:10pt;">December 31, 2019</span><span style="font-family:inherit;font-size:10pt;">, </span><span style="font-family:inherit;font-size:10pt;">two</span><span style="font-family:inherit;font-size:10pt;"> customers accounted for </span><span style="font-family:inherit;font-size:10pt;"><span>89%</span></span><span style="font-family:inherit;font-size:10pt;"> of gross accounts receivable, ESSDS, which accounted for </span><span style="font-family:inherit;font-size:10pt;"><span>77%</span></span><span style="font-family:inherit;font-size:10pt;"> of gross accounts receivable, and McKesson, which accounted for </span><span style="font-family:inherit;font-size:10pt;"><span>12%</span></span><span style="font-family:inherit;font-size:10pt;"> of gross accounts receivable. </span></div><div style="line-height:120%;padding-top:8px;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">We depend on single source suppliers for most of our products, product candidates and their active pharmaceutical ingredients, or APIs. With respect to Xyrem, the API is manufactured for us by a single source supplier and the finished product is manufactured both by us in our facility in Athlone, Ireland and by our U.S.-based Xyrem supplier.</span></div>
CY2020Q1	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	981602000	USD
CY2020Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2020Q1	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2020Q1	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	981602000	USD
CY2020Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	701602000	USD
CY2020Q1	us-gaap	Investments Investments	280000000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	1077344000	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2019Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	0	USD
CY2019Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	1077344000	USD
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	637344000	USD
CY2019Q4	us-gaap	Investments Investments	440000000	USD
CY2020Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	4400000	USD
CY2019Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	4800000	USD
CY2020Q1	us-gaap	Equity Securities Without Readily Determinable Fair Value Amount EquitySecuritiesWithoutReadilyDeterminableFairValueAmount	4500000	USD
CY2020Q1	us-gaap	Derivative Asset Fair Value Gross Asset Including Not Subject To Master Netting Arrangement DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement	316000	USD
CY2020Q1	us-gaap	Derivative Liability Fair Value Gross Liability Including Not Subject To Master Netting Arrangement DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement	10110000	USD
CY2019Q4	us-gaap	Derivative Asset Fair Value Gross Asset Including Not Subject To Master Netting Arrangement DerivativeAssetFairValueGrossAssetIncludingNotSubjectToMasterNettingArrangement	2508000	USD
CY2019Q4	us-gaap	Derivative Liability Fair Value Gross Liability Including Not Subject To Master Netting Arrangement DerivativeLiabilityFairValueGrossLiabilityIncludingNotSubjectToMasterNettingArrangement	1697000	USD
CY2020Q1	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	13901000	USD
CY2019Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	13595000	USD
CY2020Q1	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	37689000	USD
CY2019Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	36658000	USD
CY2020Q1	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	34020000	USD
CY2019Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	28355000	USD
CY2020Q1	us-gaap	Inventory Net InventoryNet	85610000	USD
CY2019Q4	us-gaap	Inventory Net InventoryNet	78608000	USD
CY2019Q4	us-gaap	Goodwill Goodwill	920018000	USD
CY2020Q1	us-gaap	Goodwill Foreign Currency Translation Gain Loss GoodwillForeignCurrencyTranslationGainLoss	-10792000	USD
CY2020Q1	us-gaap	Goodwill Goodwill	909226000	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3167245000	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	928587000	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2238658000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	3292501000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	990850000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2301651000	USD
CY2020Q1	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	3167245000	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	928587000	USD
CY2020Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2238658000	USD
CY2019Q4	us-gaap	Intangible Assets Gross Excluding Goodwill IntangibleAssetsGrossExcludingGoodwill	3431827000	USD
CY2019Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	990850000	USD
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2440977000	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	186372000	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	203041000	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	159167000	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	159167000	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	159167000	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	1371744000	USD
CY2020Q1	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2238658000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	185005000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	186763000	USD
CY2020Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	55443000	USD
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	55257000	USD
CY2020Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	129562000	USD
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	131506000	USD
CY2020Q1	jazz	Accrued Rebates And Other Sales Deductions AccruedRebatesAndOtherSalesDeductions	121369000	USD
CY2019Q4	jazz	Accrued Rebates And Other Sales Deductions AccruedRebatesAndOtherSalesDeductions	96860000	USD
CY2020Q1	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	52080000	USD
CY2019Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	80290000	USD
CY2020Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	12357000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	12728000	USD
CY2020Q1	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	8663000	USD
CY2019Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1037000	USD
CY2020Q1	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	8443000	USD
CY2019Q4	us-gaap	Accrued Marketing Costs Current AccruedMarketingCostsCurrent	11299000	USD
CY2020Q1	jazz	Accrued Inventory Related Liabilities AccruedInventoryRelatedLiabilities	7706000	USD
CY2019Q4	jazz	Accrued Inventory Related Liabilities AccruedInventoryRelatedLiabilities	7816000	USD
CY2020Q1	jazz	Sales Return Reserve SalesReturnReserve	4519000	USD
CY2019Q4	jazz	Sales Return Reserve SalesReturnReserve	3462000	USD
CY2020Q1	jazz	Accrued Collaboration Costs Current AccruedCollaborationCostsCurrent	3865000	USD
CY2019Q4	jazz	Accrued Collaboration Costs Current AccruedCollaborationCostsCurrent	2494000	USD
CY2020Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	3495000	USD
CY2019Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4718000	USD
CY2020Q1	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	2654000	USD
CY2019Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	6931000	USD
CY2020Q1	jazz	Accrued Interest AccruedInterest	2520000	USD
CY2019Q4	jazz	Accrued Interest AccruedInterest	7386000	USD
CY2020Q1	jazz	Accrued Clinical Trial Liability AccruedClinicalTrialLiability	2473000	USD
CY2019Q4	jazz	Accrued Clinical Trial Liability AccruedClinicalTrialLiability	2551000	USD
CY2020Q1	jazz	Accrued Construction In Progress AccruedConstructionInProgress	256000	USD
CY2019Q4	jazz	Accrued Construction In Progress AccruedConstructionInProgress	1564000	USD
CY2020Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	30641000	USD
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	28737000	USD
CY2020Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	261041000	USD
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	267873000	USD
CY2020Q1	us-gaap	Long Term Debt LongTermDebt	1610371000	USD
CY2019Q4	us-gaap	Long Term Debt LongTermDebt	1607257000	USD
CY2020Q1	us-gaap	Long Term Debt Current LongTermDebtCurrent	33387000	USD
CY2019Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	33387000	USD
CY2020Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1576984000	USD
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	1573870000	USD
CY2020Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	25040000	USD
CY2020Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	608387000	USD
CY2020Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	33387000	USD
CY2020Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	517494000	USD
CY2020Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	575000000	USD
CY2020Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	1759308000	USD
CY2020Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	5290000	USD
CY2019Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	5870000	USD
CY2020Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	870000	USD
CY2019Q1	us-gaap	Short Term Lease Cost ShortTermLeaseCost	601000	USD
CY2020Q1	us-gaap	Variable Lease Cost VariableLeaseCost	1000	USD
CY2019Q1	us-gaap	Variable Lease Cost VariableLeaseCost	3000	USD
CY2020Q1	us-gaap	Sublease Income SubleaseIncome	157000	USD
CY2019Q1	us-gaap	Sublease Income SubleaseIncome	162000	USD
CY2020Q1	us-gaap	Lease Cost LeaseCost	6004000	USD
CY2019Q1	us-gaap	Lease Cost LeaseCost	6312000	USD
CY2020Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	135976000	USD
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	139385000	USD
CY2020Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	12357000	USD
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	12728000	USD
CY2020Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	147110000	USD
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	151226000	USD
CY2020Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	159467000	USD
CY2019Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	163954000	USD
CY2020Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y7M6D
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y8M12D
CY2020Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.053
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.053
CY2020Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	6215000	USD
CY2019Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	4576000	USD
CY2020Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	201000	USD
CY2019Q1	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	151029000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	15097000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	21023000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	21044000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	21368000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	23711000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	104655000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	206898000	USD
CY2020Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	47431000	USD
CY2020Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	159467000	USD
CY2020Q1	us-gaap	Unrecorded Unconditional Purchase Obligation Balance On First Anniversary UnrecordedUnconditionalPurchaseObligationBalanceOnFirstAnniversary	90500000	USD
CY2020Q1	us-gaap	Oci Before Reclassifications Net Of Tax Attributable To Parent OciBeforeReclassificationsNetOfTaxAttributableToParent	-34190000	USD
CY2020Q1	us-gaap	Reclassification From Aoci Current Period Net Of Tax Attributable To Parent ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent	-147000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-34043000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-157833000	USD
CY2019Q1	us-gaap	Net Income Loss NetIncomeLoss	85201000	USD
CY2020Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	55956000	shares
CY2019Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	57206000	shares
CY2020Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	0	shares
CY2019Q1	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements	875000	shares
CY2020Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	55956000	shares
CY2019Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58081000	shares
CY2020Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.82
CY2019Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.49
CY2020Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.82
CY2019Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.47
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	534726000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	508186000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	534726000	USD
CY2019Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	508186000	USD
CY2019Q4	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	9581000	USD
CY2020Q1	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	1180000	USD
CY2020Q1	us-gaap	Contract With Customer Liability ContractWithCustomerLiability	8401000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	28654000	USD
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	27552000	USD
CY2020Q1	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	3746000	USD
CY2019Q1	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	3667000	USD
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	24908000	USD
CY2019Q1	us-gaap	Allocated Share Based Compensation Expense Net Of Tax AllocatedShareBasedCompensationExpenseNetOfTax	23885000	USD
CY2020Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-51300000	USD
CY2019Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	29100000	USD
CY2020Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.245
CY2019Q1	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.253

Files In Submission

Name	View Source	Status
0001232524-20-000034-index-headers.html	Edgar Link	pending
0001232524-20-000034-index.html	Edgar Link	pending
0001232524-20-000034.txt	Edgar Link	pending
0001232524-20-000034-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
jazz-20200331.xsd	Edgar Link	pending
jazz-20200331_cal.xml	Edgar Link	unprocessable
jazz-20200331_def.xml	Edgar Link	unprocessable
jazz-20200331_lab.xml	Edgar Link	unprocessable
jazz-20200331_pre.xml	Edgar Link	unprocessable
jazz2020q1doc.htm	Edgar Link	pending
jazz2020q1doc_htm.xml	Edgar Link	completed
jazzq12020ex101.htm	Edgar Link	pending
jazzq12020ex102.htm	Edgar Link	pending
jazzq12020ex103.htm	Edgar Link	pending
jazzq12020ex104.htm	Edgar Link	pending
jazzq12020ex311.htm	Edgar Link	pending
jazzq12020ex312.htm	Edgar Link	pending
jazzq12020ex321.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R9999.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$JAZZ
Jazz Pharmaceuticals PLC Stock $jazz

2020 Q1 Form 10-Q Financial Statement

#000123252420000034 Filed on May 05, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$JAZZ Jazz Pharmaceuticals PLC Stock $jazz

2020 Q1 Form 10-Q Financial Statement

#000123252420000034 Filed on May 05, 2020

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$JAZZ
Jazz Pharmaceuticals PLC Stock $jazz